Ocular Therapeutix (OCUL) Preferred Stock Liabilities (2013 - 2014)
Ocular Therapeutix (OCUL) posted quarterly Preferred Stock Liabilities of $74.4 million for Q2 2014, little changed on a QoQ basis from $74.3 million in Q4 2013.
Ocular Therapeutix (OCUL) Preferred Stock Liabilities (2013 - 2014) Analysis & Trends
Ocular Therapeutix has reported Preferred Stock Liabilities for 2 years, with the latest figure at $74.4 million in Q2 2014.
- Preferred Stock Liabilities for Q2 2014 came in at $74.4 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2014 was $74.4 million (changed N/A YoY), and the FY2013 annual result was $74.3 million, changed N/A from the prior year.
- Preferred Stock Liabilities held at $74.4 million in Q2 2014, from $74.3 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $74.4 million in Q2 2014 and troughed at $74.3 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | 74.36 Mn |
| Dec 31, 2013 | 74.34 Mn |